Physician profile
Neil A Schultz
NPI 1811962814
$10,285.02
in general payments reported to CMS, 2019-2025
31 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2020: $987 · 2021: $1,161 · 2022: $1,245 · 2023: $1,645 · 2024: $2,204 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,386 · Debt Forgiveness: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.90 |
| Debt Forgiveness | $230.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,969.63 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,283.70 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,027.79 | 2019-2025 | Ozempic, Wegovy |
| Boston Scientific Corporation | $803.32 | 2019-2024 | Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals Lp | $762.88 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $556.22 | 2020-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $481.00 | 2019-2025 | |
| Medtronic, INC. | $449.51 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $315.83 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $261.61 | 2019-2022 | |
| Ge Healthcare | $230.05 | 2024 | |
| Pfizer INC. | $223.03 | 2019-2025 | |
| Abbott Laboratories | $211.08 | 2019-2024 | Proclaim |
| Heartflow, INC. | $201.21 | 2024 | |
| Amgen INC. | $178.59 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $172.26 | 2019-2025 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $167.92 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $161.45 | 2019 | |
| Atricure, INC. | $146.91 | 2023 | |
| Amarin Pharma, INC. | $140.49 | 2019-2022 | |
| Procept Biorobotics Corporation | $117.27 | 2023 | Aquabeam Robotic System |
| Medtronic Vascular, INC. | $109.61 | 2019 | |
| Cvrx, INC. | $81.18 | 2024-2025 | Barostim Neo System |
| Glaxosmithkline, LLC. | $61.51 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.31 | 2021-2022 | |
| Esperion Therapeutics, INC. | $20.02 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $18.29 | 2024 | Arcalyst |
| Sunovion Pharmaceuticals INC. | $16.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.88 | 2024 | Onpattro |
| Amryt Pharma Holdings Ltd | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.